Cutaneous T-cell lymphoma cells are sensitive to rapamycin

Experimental Dermatology

Volumn 19, Issue 9, 2010, Pages 800-805

  Kremer, Melanie ^a   Sliva, Katja ^a   Klemke, Claus Detlev ^b   Schnierle, Barbara S ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CTCL; MTOR; Rapamycin

Indexed keywords

RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; SEZARY SYNDROME; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MICE, NUDE; SEZARY SYNDROME; SIGNAL TRANSDUCTION; SIROLIMUS; SKIN NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 77955730714     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01102.x     Document Type: Article

References (28)

1. Kim E J, Hess S, Richardson S K. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005, 115:798-812.
2. Querfeld C, Guitart J, Kuzel T M, Rosen S T. Primary cutaneous lymphomas: a review with current treatment options. Blood Rev 2003, 17:131-142.
3. Edelson R L. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann N Y Acad Sci 2001, 941:1-11.
4. Dummer R, Assaf C, Bagot M. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer 2007, 43:2321-2329.
5. Kaltoft K, Hansen B H, Thestrup-Pedersen K. Cytogenetic findings in cell lines from cutaneous T-cell lymphoma. Dermatol Clin 1994, 12:295-304.
6. Kaltoft K, Bisballe S, Rasmussen H F, Thestrup-Pedersen K, Thomsen K, Sterry W. A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 1987, 279:293-298.
7. Thaler S, Burger A M, Schulz T. Establishment of a mouse xenograft model for mycosis fungoides. Exp Dermatol 2004, 13:406-412.
8. Reinhold U, Abken H. Cutaneous T-cell lymphoma: molecular genetics, immunology and pathogenesis. Eur J Cancer 1995, 31A:793-799.
9. Berger C L, Tigelaar R, Cohen J. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005, 105:1640-1647.
10. Boehncke W H, Gerdes J, Wiese M, Kaltoft K, Sterry W. A majority of proliferating T cells in cutaneous malignant T cell lymphomas may lack the high affinity IL-2 receptor (CD25). Arch Dermatol Res 1993, 285:127-130.
11. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin J Z, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998, 92:252-258.
12. Gootenberg J E, Ruscetti F W, Mier J W, Gazdar A, Gallo R C. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med 1981, 154:1403-1418.
13. Mills R E, Jameson J M. T cell dependence on mTOR signaling. Cell Cycle 2009, 8:545-548.
14. Marzec M, Liu X, Kasprzycka M. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 2008, 111:2181-2189.
15. Gao N, Flynn D C, Zhang Z. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004, 287:C281-C291.
16. Ho C L, Sheu L F, Li C Y. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2002, 10:316-321.
17. Krejsgaard T, Vetter-Kauczok C S, Woetmann A. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006, 20:1759-1766.
18. Harris A L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
19. Charley M R, Tharp M, Locker J. Establishment of a human cutaneous T-cell lymphoma in C.B-17 SCID mice. J Invest Dermatol 1990, 94:381-384.
20. Frei G M, Kremer M, Hanschmann K M. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101. Br J Dermatol 2008, 158:578-586.
21. Thaler S, Burger A M, Schulz T, Schnierle B S. MLV/HIV-pseudotyped vectors: a new treatment option for cutaneous T cell lymphomas. Mol Ther 2003, 8:756-761.
22. Dong X, Han Z C, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 2007, 62:105-118.
23. El Hashemite N, Walker V, Zhang H, Kwiatkowski D J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003, 63:5173-5177.
24. Weischer M, Rocken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol 2007, 16:385-393.
25. Ormerod A D, Shah S A, Copeland P, Omar G, Winfield A. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 2005, 152:758-764.
26. Rini B I. Molecularly targeted therapy in renal cell carcinoma: where do we go from here? Expert Rev Anticancer Ther 2006, 6:1753-1760.
27. Smith S M. Clinical development of mTOR inhibitors: a focus on lymphoma. Rev Recent Clin Trials 2007, 2:103-110.
28. Witzig T E, Kaufmann S H. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006, 7:285-294.